Improved Characterization of Brain Tumors By MRI and MRS
- Determine the magnetic resonance spectroscopic imaging (MRSI) characteristics of
patients who are undergoing treatment for supratentorial glioma.
- Determine the survival of patients who undergo magnetic resonance imaging and MRSI.
- Determine the clinical outcome of patients who undergo these imaging procedures.
- Correlate measures of metabolic tumor burden (i.e., CNI, CCCrI, CrNI, and LLI) with
survival and clinical outcome in patients who undergo these imaging procedures.
- Determine the time to clinical progression in patients who undergo these imaging
OUTLINE: Patients are assigned to 1 of 2 treatment groups based on grade of disease.
- Group 1 (patients with grade II glioma): Patients undergo magnetic resonance imaging
(MRI) and magnetic resonance spectroscopic imaging (MRSI). Patients then receive
chemotherapy. Patients undergo repeat MRI/MRSI after courses 2 and 4 of chemotherapy.
- Group 2 (patients with grade III-IV glioma): Patients undergo MRI/MRSI and then undergo
surgical resection of the tumor. Patients then receive chemoradiotherapy. Patients
undergo repeat MRI/MRSI within 2 weeks and at 2 months after completion of
Patients are followed for recurrence, disease progression, and survival.
PROJECTED ACCRUAL: A total of 250 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Diagnostic
Sarah J. Nelson, PhD
University of California, San Francisco
United States: Federal Government
|UCSF Helen Diller Family Comprehensive Cancer Center||San Francisco, California 94115|